Organ transplant immunosuppressant drugs are the category of drugs which are administered to minimize the chances of organ rejection after transplantation. When a person undergoes any transplantation, the body recognizes the transplant as a foreign tissue and attacks it, resulting in rejection. These drugs dilute the immune system, hence reducing the reaction towards the transplant. The factors driving this market include the advancements made in tissue engineering and organ transplantations. These transplantations help in survival of many patients as well as enhance the quality of life. The lack of availability of organs and high cost of transplantation are the limitations for the growth of this market. The increase in use of tissue engineering for generation of implants provides growth opportunity to this market.
GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS THERAPEUTICS MARKET ANALYSIS
On the basis of therapeutics, this market is classified into heart transplant, lung transplant, kidney transplant and liver transplant. Kidney transplant has a well established market although heart transplant is expected to have potential growth.
ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS GEOGRAPHY MARKET ANALYSIS
On the basis of geography, this market is classified into North America, Europe, Asia-Pacific and rest of the world (RoW). Asia-Pacific region is expected to have greater share in this market in the coming years. This growth would be due to promotion of medical tourism in these countries.
The major companies included in the report are AstellasPharma, Genzyme Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc., Novartis AG, Mylan Laboratories, Inc., GlaxoSmithKline plc, and Hoffman La Roche. Key companies in the report are seeking for approval strategy for the commercialization of their pipeline drugs. Therefore, the companies are adopting approval and clearance as key developmental strategies.
HIGH LEVEL ANALYSIS
Organ transplant immunosuppressant drugs market has accelerated the growth of rapid organ transplant by reducing the harmful side effects such as autoimmune diseases. These novel drug therapies are strategically analyzed in the report in order to provide comparative benefits. The report is also focusing on the regulatory issues and commercial mandate that are hindering the growth. Porter’s five forces model is strategically analyzed in the report to project current and future market scenarios. The value chain analysis of the organ transplant immunosuppressant drugs market is dealt strategically. Top wining strategies adopted by the key players competing in this market are critically analyzed through primaries.
KEY MARKET SEGMENTS
The global Organ transplant immunosuppressant drugs market is segmented into therapeutics, commercialized products and geography.
MARKET BY THERAPEUTICS
MARKET BY COMMERCIALIZED PRODUCTS
MARKET BY GEOGRAPHY
SIMILAR MARKET STUDIES
Summary Merck Canada Inc. (Merck Canada) is a pharmaceutical company. The company develops, manufactures and markets pharmaceutical products for various therapy areas. It operates through product segments, such as vaccines, prescription products, consumer products and animal health. The company’s consumer products include CLARITIN, AERIUS, and CHLOR-TRIPOLON for allergies, COPPERTONE for sun ...
October 2014 | $300 | View Details >>
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 126.96.36.199) - Pipeline Review, H2 2016 Summary Global Markets Directs, Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 188.8.131.52) - ...
July 2016 | $3500 | View Details >>
Notes: Sales, means the sales volume of Drugs for Vulvovaginal Candidiasis Revenue, means the sales value of Drugs for Vulvovaginal Candidiasis This report studies sales (consumption) of Drugs for Vulvovaginal Candidiasis in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue ...
February 2017 | $4000 | View Details >>
Managed care began to be developed as early as 1917, with both private and government payers established by the mid-1960s. Medicare and Medicaid are the major government payers, with the health care reform legislation of 2010 providing changes for both.
March 2012 | $3900 | View Details >>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research